Chugai Pharmaceutical came into this Q3 2026 print with a premium story attached. The stock traded at a P/E of 21.6x against an industry level closer to the mid teens, and yet the shares closed today at ¥6,614, only modestly higher over the past month and lower over the past quarter.
The fresh numbers tell a sharper tale than the muted price move. Quarterly revenue reached ¥404,743m and basic earnings per share landed at ¥87.25, feeding into trailing earnings that support a 35.6% net margin. The core issue for investors now is simple: strong profitability sits against a valuation that still asks a lot.
Love Chugai Pharmaceutical’s 35.6% net margin but uneasy about paying a premium P/E for it? Compare this earnings profile against companies in our 16 high quality undervalued stocks
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): ¥404,743m vs. ¥333,176m (up about 21.5%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): ¥143,553m vs. ¥111,213m (up about 29.1%)
- Basic EPS (Q3 2026 vs Q3 2025): ¥87.25 vs. ¥67.58 (up about 29.1%)
- Trailing Net Margin (Last 12 Months vs Prior Year): 35.6% vs. 32.7% (margin higher by 2.9 percentage points)
Earnings prints tell you what Chugai Pharmaceutical just did, but cash flows tell you what you are really paying for over time. If you look at Chugai Pharmaceutical's cash generation and feed that into a discounted cash flow model, the stock could be a whopping 39% undervalued.
Chugai bullish case leans on real pipeline progress
The optimistic story around Chugai Pharmaceutical hangs on late stage projects and royalties turning into tangible outputs, not just promises.
"Some analysts expect Chugai Pharmaceutical to continue converting its broad late stage pipeline and higher capital investment into increased biologics output and operating efficiency as new products such as NXT007, Nemluvio and Foundayo scale."
Q3 results move this from theory to partial execution. Revenue of ¥906.8b with a roughly 50.2% core operating margin, together with ¥161.3b in royalties and milestones, shows biologics and partner income already pulling more weight. Strong Nemluvio exports to Galderma and Enspryng’s new U.S. indication help validate the scaling products piece of that bullish view.
One Narrative disagrees with today's price. → See where this Narrative says Chugai Pharmaceutical should trade.
Chugai bear case: pipeline depth still on trial
Critics worry that Chugai Pharmaceutical’s crowded slide deck hides a thinner late stage engine. That concern focuses on discontinuations and the ability to backfill Hemlibra and Actemra exposure.
"While Chugai Pharmaceutical is filing what it describes as a record number of projects in 2026, the company is also discontinuing multiple in-house programs such as tominersen, BRY10, several Tecentriq indications and GYM329 in SMA and FSHD."
Q3 results show strong royalties, exports and a filing pull forward for Divarasib and trontinemab. Yet management again highlighted program cuts and still avoided concrete FY2027 guidance. Nemluvio and Enspryng progress help, but evidence that the broader late stage queue can offset eventual Hemlibra and Actemra pressure remains incomplete.
Hunt For Quietly Mispriced Cash Flows
Chugai Pharmaceutical just reported strong earnings with a premium valuation and limited share-price reaction. The real opportunity is studying stocks that might not yet reflect their full cash-flow potential.
- Company 1 - 20% below our estimate - targets customers automating form-heavy workflows as legacy output systems restrict access to underlying data.
- Company 2 - 30% below our estimate - supplies advanced photomasks as chipmakers move into finer geometries that pressure traditional tooling capacity.
- Company 3 - 45% below our estimate - expands fee and lending franchises as smaller businesses seek a primary banking partner with broader services.
Three companies from the same screener. Open the full list of 16 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com